It was a great pleasure to meet with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the impact in the use of CGRP antagonists in migraine therapy.
The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What has been the impact of small‐molecule, oral calcitonin gene‐related peptide receptor (CGRP) antagonists such as ubrogepant on migraine therapy? (0:14)
- What is the rationale for combining ubrogepant with an anti-CGRP monoclonal antibody (mAb)? (1:28)
- What is known about the safety of coadministering these two agents? (3:10)
Disclosures: Richard Lipton reports receives research support from the NIH, FDA as well as the National Headache Foundation and the Marx Foundation; and also receives research support from Allergan/Abbvie, Amgen, Eli Lilly and Electrocore. Richard Lipton receives personal fees as a consultant or advisor from from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Novartis, Lundbeck, Merck, and Teva Pharmaceuticals; and holds stock or options in Biohaven Holdings and CtrlM Health.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!